Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
National Institutes of Health Clinical Center (CC)
Toros University
Pfizer
Eli Lilly and Company
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Travera Inc
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Memorial Sloan Kettering Cancer Center
Eastern Cooperative Oncology Group
Colorado State University
Avera McKennan Hospital & University Health Center
Orano Med LLC
Wake Forest University Health Sciences
Fondazione del Piemonte per l'Oncologia
M.D. Anderson Cancer Center
Zagazig University
Gustave Roussy, Cancer Campus, Grand Paris
Kaiser Permanente
University of Pennsylvania
Duke University
Washington University School of Medicine
MBrace Therapeutics
Ulsan University Hospital
New Phase Ltd.
University of Colorado, Denver
Unity Health Toronto
City of Hope Medical Center
University of Nebraska
EXoPERT
Memorial Sloan Kettering Cancer Center
Eli Lilly and Company
Novartis
Var2 Pharmaceuticals
Universidad Complutense de Madrid
Dokuz Eylul University
University of Salamanca
Centre Hospitalier Universitaire de Besancon
AC Camargo Cancer Center
City of Hope Medical Center
Centre Hospitalier Universitaire de Nīmes
University Health Network, Toronto
NantCell, Inc.
Vejle Hospital
City of Hope Medical Center